Chest-strap ECG wearable vs. traditional patch monitor in active adults
Official title: Feasibility and Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC)
Run by Mayo Clinic · NCT07772817 · Data updated 2026-11-12
This study tests whether the Frontier X Plus chest-strap ECG device can capture heart rhythms as well as the MoMe ARC patch in active adults who already need an ambulatory monitor.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 22 Years and up |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 3 sites (Scottsdale, Arizona and 2 other locations) |
| Status | Recruiting |
| Started | September 2026 |
| Main results expected | February 23, 2027 |
| Study ends | February 23, 2027 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT07772817 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 22 who exercise regularly (≥4 days/week, ≥150 minutes/week) and require ambulatory ECG monitoring for at least 24 hours.
✕Probably not a fit
Individuals with implanted cardiac devices, pregnancy, skin issues at the chest strap site, or inability to use a compatible mobile device may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study compares two ambulatory ECG monitoring methods in adults who exercise regularly and require ECG monitoring. Participants wear the Frontier X Plus chest-strap device and use its app for the monitoring period, alongside the standard MoMe ARC patch monitor. The goal is to see how well the Frontier X Plus performs in detecting rhythm changes during normal activity. Enrollees must meet safety and device-use criteria and do not have implanted cardiac devices or pregnancy. The study is led by Mayo Clinic at three U.S. sites.
Why it matters
Potential benefit: If successful, the Frontier X Plus could offer an alternative, comfortable monitoring option for active individuals.
How similar studies have gone: Previous studies have explored wearable ECG monitors; this study adds a direct comparison in an active population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult participants (\>22 years; Frontier X is approved for use in this age group) who participate in \>4 days a week of \>150 minutes total per week of moderate to high intensity exercise who were prescribed a ambulatory ECG monitor for clinical purposes for 24 hours or more. * Patients must agree to wear the Frontier X monitor for the prescribed duration and use the Frontier X Plus application Exclusion Criteria: * Current use of Implanted Cardiac Devices * Pregnancy * Known allergies to any of the materials listed in the "List of Patient-Contacting Materials" * Presence of skin injuries or broken skin in the area where the chest strap is worn * Inability to use a compatible mobile device required for the operation of the study device * Any cognitive or physical limitations that, in the opinion of the investigator, limits the participant's ability to fully follow study procedures * Medical restrictions on exercise for safety including cardiac, orthopedic or other relevant past medical history
Where it's running
-
Mayo Clinic Arizona
Scottsdale, Arizona, United States Recruiting -
Mayo Clinic Florida
Jacksonville, Florida, United States Recruiting -
Mayo Clinic Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Elizabeth Dineen, DO — Mayo Clinic
- Study coordinator: Elizabeth Dineen, DO
- Email: dineen.elizabeth@mayo.edu
- Phone: 904-953-5230
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BDNF Levels and Atrial Cardiomyopathy in People Having AF Ablation
This study tests whether circulating BDNF levels are linked to atrial cardiomyopathy in adults having their first ablation for persistent atrial fibrillation.
-
nano-second pulsed field (nsPFA) catheter ablation for paroxysmal atrial fibrillation using the CellFX system
The study will try the CellFX nano-second pulsed field catheter to treat adults with recurrent, drug-resistant paroxysmal atrial fibrillation.
-
Monitoring heart activity with a smart textile chest band
This study tests a smart chest band that tracks heart activity for two weeks to see if it can help spot heart rhythm problems better.
-
Using a new catheter system to treat atrial fibrillation
This study is testing a new catheter system to see if it safely helps people with paroxysmal atrial fibrillation feel better after treatment.
-
Ablation of focal activation in atrial fibrillation
This study is testing a new method to find specific electrical signals that may be causing ongoing atrial fibrillation in patients, to see if targeting these signals can improve their treatment.
-
HeartWatch vs Holter: A Longer-Term Arm Monitors Heart Rhythm
This study tests whether the HeartWatch arm monitor can match or improve on Holter monitoring for detecting rhythm problems in adults with suspected AF and other arrhythmias.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.